Aclarion (ACON) Projected to Post Quarterly Earnings on Tuesday
by Renee Jackson · The Cerbat GemAclarion (NASDAQ:ACON – Get Free Report) is projected to issue its Q4 2025 results before the market opens on Tuesday, April 14th. Analysts expect the company to announce earnings of ($2.79) per share and revenue of $0.0250 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 7:00 AM ET.
Aclarion (NASDAQ:ACON – Get Free Report) last issued its earnings results on Wednesday, March 18th. The company reported ($2.01) earnings per share for the quarter, topping the consensus estimate of ($3.60) by $1.59. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. Aclarion had a negative net margin of 9,517.11% and a negative return on equity of 52.31%. On average, analysts expect Aclarion to post $-263 EPS for the current fiscal year and $-217 EPS for the next fiscal year.
Aclarion Price Performance
ACON stock opened at $3.23 on Monday. The company’s 50 day simple moving average is $3.02 and its 200-day simple moving average is $5.18. The firm has a market capitalization of $7.37 million, a PE ratio of -0.19 and a beta of 1.13. Aclarion has a 12 month low of $2.34 and a 12 month high of $12.03.
Wall Street Analyst Weigh In
Several analysts have recently commented on the stock. Wall Street Zen upgraded shares of Aclarion from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.
Check Out Our Latest Report on ACON
Aclarion Company Profile
Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.